Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Oncology Conferences to Watch in the Second Half of 2025

August 20th 2025

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.

Dr Gupta on Updated Efficacy Data With Liso-Cel in Second-Line Relapsed/Refractory LBCL

August 19th 2025

Supriya Gupta, MD, discusses updated efficacy data on liso-cel as second-line therapy for large B-cell lymphoma.

Dr Ku on the Rationale for Evaluating JNJ-90014496 in Relapsed/Refractory LBCL

August 19th 2025

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, details the rationale for assessing a dual bispecific CAR T-cell therapy in relapsed/refractory LBCL.

Removal of REMS Requirements Improves Access to CAR T-Cell Therapy Across Hematologic Malignancies

August 18th 2025

Four expert hematologists discuss the FDA’s decision to remove REMS programs for CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies.

Five Under 5: Top Oncology Videos for the Week of 8/10

August 17th 2025

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

The OncFive: Top Oncology Articles for the Week of 8/10

August 16th 2025

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Dr Pemmaraju on Responses With Pivekimab Sunirine in Frontline and R/R CD123+ BPDCN

August 15th 2025

Naveen Pemmaraju, MD, discusses phase 2 data with pivekimab sunirine in frontline or relapsed/refractory blastic plasmacytoid dendritic cell neoplasms.

Clinical Development Is Discontinued for SGR-2921 in R/R AML and Higher-Risk MDS

August 15th 2025

The development of SGR-2921 in relapsed/refractory AML and higher-risk MDS was discontinued followed by 2 patient deaths.

Real-World Data Highlight Feasibility of CAR T-Cell Therapy in Patients With Aggressive Lymphomas and Active Autoimmune Disease

August 14th 2025

Retrospective data showed CAR T-cell therapy is feasible in patients with aggressive lymphomas and active autoimmune diseases.

CD19 t-haNK Leads to Complete Responses in Waldenstrom Macroglobulinemia

August 13th 2025

CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.

Dr Gopal on the FDA Approval of Tafasitamab in R/R Follicular Lymphoma

August 13th 2025

Ajay K. Gopal, MD, FACP, discusses the significance of the FDA approval of tafasitamab for patients with relapsed/refractory follicular lymphoma.

The OncFive: Top Oncology Articles for the Week of 8/3

August 9th 2025

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

Epcoritamab Plus Rituximab and Lenalidomide Hits Both Primary End Points in R/R Follicular Lymphoma

August 7th 2025

Epcoritamab plus rituximab and lenalidomide met the dual primary end points of the EPCORE FL-1 in relapsed/refractory follicular lymphoma.

FDA Approves Tocilizumab Biosimilar for CAR T-Cell Therapy–Induced CRS

August 6th 2025

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology

August 6th 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Investigation of SENTI-202 in R/R AML Continues After Confirming RP2D

August 5th 2025

A dose-expansion cohort will further evaluate SENTI-202 in relapsed/refractory acute myeloid leukemia.

FDA Grants Priority Review to Liso-Cel for R/R Marginal Zone Lymphoma

August 4th 2025

The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

EMA Grants PRIME Designation to BGB-16673 for Previously Treated Waldenström Macroglobulinemia

August 4th 2025

The BTK degrader BGB-16673 has received PRIME designation from the EMA for the treatment of patients with Waldenström macroglobulinemia.

ALPHA3 Trial of Cema-Cel in LBCL Proceeds With Fludarabine/Cyclophosphamide Lymphodepletion Regimen

August 4th 2025

Fludarabine plus cyclophosphamide lymphodepletion will be used in the phase 2 ALPHA3 trial of first-line consolidation cema-cel in patients with LBCL.

Voices in Lymphoma: Women Shaping the Future of Care

August 4th 2025

Clémentine Sarkozy, MD, PhD, and Carla Casulo, MD, detail the evolution of lymphoma management strategies.